- Home
- CMBM vs DXR Comparison
CMBM vs DXR Comparison
Compare CMBM & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | DXR |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.5M | 69.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMBM | DXR |
|---|---|---|
| Price | $1.54 | $12.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 355.4K | 7.1K |
| Earning Date | 02-19-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $172,215,000.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | ★ N/A | $36.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $6.55 |
| 52 Week High | $6.80 | $14.76 |
Technical Indicators
Market Signals| Indicator | CMBM | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 44.72 |
| Support Level | $1.52 | $12.21 |
| Resistance Level | $1.68 | $14.00 |
| Average True Range (ATR) | 0.13 | 0.59 |
| MACD | -0.00 | -0.12 |
| Stochastic Oscillator | 35.53 | 31.93 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.